B1AX34.SA Baxter International Inc.
- Market cap
- BRL 64.3B
- P/E
- -
- P/B
- 1.82x
- ROE
- 8.3%
- Dividend yield
- 0.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is B1AX34.SA undervalued?
Graham numberThe Graham number of Baxter International Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Baxter International Inc. fundamental analysis
No fundamental analysis for Baxter International Inc. yet.
Baxter International Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipm…
Full company profileBaxter International Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Baxter International Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 11.1B | 11.4B | 11.7B | 12.8B | 10.1B | 10.4B | 10.6B | 11.2B | 11.5B |
| Gross Profit | 4.78B | 4.76B | 4.59B | 5.11B | 3.56B | 4.18B | 4.05B | 3.45B | 3.89B |
| Operating Income | 1.65B | 876M | 1.55B | 1.69B | -2.85B | 673M | 14.0M | -297M | 677M |
| EBITDA | 2.57B | 1.87B | 2.27B | 2.57B | -1.76B | 1.73B | 1.12B | 766M | 2.02B |
| Net Income | 1.62B | 1.00B | 1.10B | 1.28B | -2.43B | 2.66B | -649M | -957M | 540M |
| EPS | 3.17 | 1.98 | 2.18 | 2.56 | -4.82 | 5.23 | -1.27 | -1.86 | 1.04 |
| Balance Sheet | |||||||||
| Total Assets | 15.6B | 18.2B | 20.0B | 33.5B | 28.3B | 28.3B | 25.8B | 20.1B | 19.4B |
| Total Liabilities | 7.83B | 10.3B | 11.3B | 24.4B | 22.5B | 19.8B | 18.8B | 14.0B | 12.9B |
| Shareholders' Equity | 7.79B | 7.88B | 8.69B | 9.08B | 5.83B | 8.40B | 6.96B | 6.13B | 6.50B |
| Cash & Short-term Investments | 1.83B | 3.34B | 3.73B | 2.95B | 1.72B | 3.19B | 1.76B | 1.97B | 1.98B |
| Cash Flow | |||||||||
| Operating Cash Flow | 2.02B | 2.10B | 1.87B | 2.22B | 1.21B | 1.73B | 1.02B | 845M | 1.41B |
| Capital Expenditure | 659M | 696M | 709M | 743M | 679M | 692M | 446M | 513M | 488M |
| Free Cash Flow | 1.42B | 1.41B | 1.16B | 1.48B | 532M | 1.03B | 559M | 323M | 920M |
| Ratios | |||||||||
| ROE | 20.8% | 12.7% | 12.7% | 14.1% | -41.7% | 31.6% | -9.3% | -15.6% | 8.3% |
| ROA | 10.4% | 5.5% | 5.5% | 3.8% | -8.6% | 9.4% | -2.5% | -4.8% | 2.8% |
| Net Profit Margin | 14.6% | 8.8% | 9.4% | 10.0% | -24.2% | 25.6% | -6.1% | -8.5% | 4.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Baxter International Inc. dividends
- Dividend yield
- 0.12%
- Forward dividend
- 0.08 BRL
- Payout ratio
- -
- Ex-dividend date
- Aug 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 348M | 0.68 | - |
| 2024 | USD 590M | 1.15 | - |
| 2023 | USD 586M | 1.15 | 22.1% |
| 2022 | USD 573M | 1.14 | - |
| 2021 | USD 530M | 1.06 | 41.3% |
| 2020 | USD 473M | 0.94 | 42.9% |
| 2019 | BRL 423M | 0.84 | 42.3% |
| 2018 | BRL 376M | 0.73 | 23.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Baxter International Inc.
Ownership data of Baxter International Inc. is not available yet.
Baxter International Inc. company profile
- Company name
- Baxter International Inc.
- Ticker
- B1AX34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 37,500
- Fiscal year end
- December
- Address
- One Baxter Parkway, Deerfield, IL, United States, 60015
- Phone
- 224 948 2000
- Website
- baxter.com
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Inc. management
10- Mr. Andrew P. HiderCEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director · born 1977
- Mr. David S. RosenbloomExecutive VP & General Counsel · born 1960
- Ms. Maria SorianoGroup President of Infusion Therapies & Platforms
- Mr. John Terence RogersExecutive VP & CFO · born 1969
- Mr. Bernie HeineInterim Chief Accounting Officer & Controller · born 1986
- Mr. Charles PatelSenior VP & Chief Information Officer · born 1970
- Mr. Kevin MoranVice President & Head of Investor Relations
- Ms. Stacey EisenSVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation
- Ms. Cynthia CarlisleExecutive VP & Chief Human Resources Officer · born 1975
- Mr. James W. BorziExecutive VP & Chief Supply Chain Officer · born 1963